An early clinical study of the monoclonal antibody daratumumab (Darzalex) in combination with the checkpoint inhibitor atezolizumab in patients with non-small cell lung cancer has been stopped early because of lack of efficacy as well as safety issues, Genmab A/S announced on 26 May.
